Thirty-seven venture-backed companies in the San Diego area collected almost $350 million in new funding during the first three months of 2017, according to data released this week as part of the latest Venture Monitor report from the National Venture Capital... Read more »
[Updated 4/6/17, 7:42 pm. See below.] Consumers who aren’t squeamish about spitting into a tube and sending it to a lab can now have 23andMe test those samples to assess their risk of developing Parkinson’s, Alzheimer’s, and eight other... Read more »
The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump administration’s proposed budget cuts in science funding.
For Biden, it’s... Read more »
A little over two years ago, President Obama laid out his vision for one of the nation’s most ambitious medical research programs—an effort to amass genomic data from at least 1 million Americans.
The big idea behind the president’s Precision... Read more »
Amid the ongoing conversation about gender discrimination in the tech industry, and recent sexual harassment claims against some of its biggest names, here’s some sort-of good news about women in tech:
When companies make job offers to both men and women,... Read more »
As bacteria develop resistance to older antibiotics, doctors are clamoring for new options that work on these drug- resistant strains. Zavante Therapeutics has been researching one drug as a possible alternative and, with results from a key clinical trial now in... Read more »
In what passes for a short hearing these days in Washington, DC, the Trump White House’s pick to run the Food and Drug Administration, Scott Gottlieb, spent less than three hours fielding questions from a Senate committee Wednesday morning.
Amid predictable... Read more »
Is a caution flag flying?
While U.S. venture firms refueled last year by raising a near-record $51.6 billion, they also eased off the throttle in terms of their investment activity during the first quarter of 2017, according to data released... Read more »
Viracta Therapeutics, a San Diego anti-cancer biotech that has been operating below the radar for nearly two years, is today disclosing an initial closing on what could amount to as much as $18.4 million in Series B financing.
Viracta plans to... Read more »